4. 'Not only did satisfactory performance criteria range from 70% to 100% from subspecialty to subspecialty, but also they varied from one state to another. As a result of these inconsistencies in monitoring proficiency testing, pass/fail standards, and grading criteria, certain affiliated laboratories operating in different states would sometimes find themselves involved in an adverse action in one state as a result of proficiencytesting results but would have no adverse action in another state for the same testing scores. Depending on the analyte, some states gave notice to a laboratory after a single failure in one testing event.
specifying that HCFA was responsible for developing the regulations relating to Medicare and CLIA '67 laboratories and that CDC was responsible for providing the scientific and technical expertise on questions related to advances in instrumentation, new technology, and proficiency testing.
CDC was responsible for providing an approved proficiency-testing program and for determining successful participation for those laboratories participating in the CLIA '67 program.
The proficiency testing managed by CDC was very prescriptive in terms of program content, frequency of shipments or testing events, grading criteria for individual analytes, and the number of challenges; the CDC determined that unsuccessful participation was defined as three consecutive unsatisfactory results or three unsatisfactory results out of four consecutive shipments for specialty, subspecialty, or analyte. Unsuccessful participation in the proficiency-testing program resulted in an action to revoke or limit the CLIA '67 license. For laboratories participating in both CLIA '67 and the Medicare programs, the results of the CDC proficiency testing and any action to revoke or limit the CLIA '67 license based on unsuccessful 4. 'Not only did satisfactory performance criteria range from 70% to 100% from subspecialty to subspecialty, but also they varied from one state to another. As a result of these inconsistencies in monitoring proficiency testing, pass/fail standards, and grading criteria, certain affiliated laboratories operating in different states would sometimes find themselves involved in an adverse action in one state as a result of proficiencytesting results but would have no adverse action in another state for the same testing scores. Depending on the analyte, some states gave notice to a laboratory after a single failure in one testing event.
5. Also, because Medicare approval was based on specialties and subspecialties of service, failure of an analyte jeopardized the entire specialty and subspecialty under Medicare.
In response to these numerous problems, CDC established a task force that developed a model proficiencytesting regulatory scheme, which was later incorporated into the March 14, 1990, final rule.
After numerous meetings between HCFA, CDC, the Food and Drug Administration, other federal agencies, state health officials, various private-sector organizations, concerned members of the laboratory industry, and the public, it was decided to consolidate all of the CLIA '67 and Medicare/Medicaid laboratory requirements. In August of 1988, HCFA published a proposed rule to revise the federal regulations. A major goal of this proposed regulation was to have, to the extent possible, the same requirements for laboratories participating in either CLIA '67, the Medicare/Medicaid programs, or both.
On October 31, 1988, Congress enacted the Clinical Laboratory Improvement Amendment of 1988 (CLIA '88). With the enactment of CLIA '88, it was necessary to evaluate the proposed revisions to the federal requirements for laboratories to ensure that the requirements would be appropriate under CLIA '88. We determined that our proposed requirements were consistent with the standards to be established under CLIA '88. Therefore, on March 14, 1990, the proposal was published as a final rule and constitutes the current regulations for laboratories performing interstate testing and (or) participating in the Medicare/Medicaid programs. The final rule contains the self-implementing provisions of CLIA '88, specifically the cytology standards and some of the proficiency-testing requirements. Most importantly, it forms the framework for establishing the CLIA '88 standards for quality control, quality assurance, record keeping, and proficiency testing.
The proficiency-testing requirements in the current regulations incorporated the changes in Section 353 of the Public Health Service Act and the recommendations and major changes suggested by CDC. This resulted in specific language defining enrollment in a program, testing of samples, successful participation, reinstatement after proficiency-testing failure, and approval and disapproval procedures for proficiency-testing programs. Enrollment and successful participation have been made conditions in this rule. The current requirements emphasize the increased importance of evaluating and achieving a passing score on samples of known content, which are tested as if they were patients' samples and serve as a measure of laboratory quality.
The regulations now contain the criteria necessary to become an approved proficiency-testing program, which include for each specialty and subspecialty: program content, frequency of challenge, number of challenges per quarter (the total number of samples for each analyte per testing event is now five), format for reporting results, reporting time frames, and criteria for acceptable performance. The criteria for grading were developed through an evaluation of the current criteria in use by state and private-sector programs and an evaluation of the data CDC had for laboratory performance in their proficiency-testing program.
In addition, each specialty and subspecialty has re- Today, under current regulations, CLIA-certified and Medicare-approved laboratories are required to enroll in an approved proficiency-testing program for each specialty and subspecialty of service for which they seek Medicare approval or CLIA certification:
they must notify HCFA of the proficiency-testing program chosen; remain within the program for at least 1 year; notify HCFA before changing proficiency-testing programs; allow the proficiency-testing program to release to HCFA or its agents all data needed to evaluate laboratory performance; test the proficiency-testing samples in the laboratory's routine manner-i.e., test proficiencytesting samples within patient-specimen runs (by the personnel who usually perform the laboratory testing); attest on the proficiency-testing result form that profi-
ciency-testing samples
were tested according to the laboratory's routine procedures for handling and testing patients' specimens; and refrain from discussing proficiency-testing results with other testing facilities until after the reporting date to the proficiency-testing program.
Satisfactory participation is defined as obtaining a grade of 80% for each analyte, specialty, and subspecialty, with the exception of 100% accuracy required for ABO and Rh grouping and compatibility testing in imniunohematology.
For any unsatisfactory testing event, the laboratory is required to seek appropriate training and to use the necessary technical assistance to correct the problems associated with the unsatisfactory result. "Unsuccessful participation" is defined as two consecutive or two-out-of-three unsatisfactory testing events for the specialty or subspecialty, or two-out-ofthree unsatisfactory scores for the same analyte. if a laboratory fails to perform successfully for a given subspecialty, CLIA certification will be terminated and Medicare disapproved only for that subspecialty. If a laboratory fails to perform successfully for a given analyte, CLIA certification or Medicare/Medicaid approval will be terminated in the subspecialty that includes that failed analyte. However, to prevent termination in the subspecialty, a laboratory may elect to voluntarily withdraw from performing tests on patients' specimens and reporting results for the unsuccessful analyte, while continuing to perform and report results for the other analytes in that subspecialty.
if a laboratory fails to participate in a proficiencytesting event, consideration may be given before an For the subspecialty of cytology, the proficiency-testing regulations require each individual who examines gynecological cytology slides to participate in two proficiency-testing events per year. Once a year, one unannounced proficiency-testing event will be conducted on site in each laboratory. In addition, at least four proficiency-testing events will be conducted of site at designated testing sites. An individual must score 80% on the cytology proficiency-testing event to achieve a satisfactory score. If an individual fails a cytology proficiency-testing event, immediate remedial training and education in the area of failure must be provided, and all subsequent gynecological slides must be re-examined by another individual who has demonstrated successful cytology proficiency-testing participation, until that individual achieves a score of 80% on the next testing event. In addition, at least the last 500 slides exnmined by an individual qualified as a technical supervisor who failed a proficiency-testing event must be re-eynmined by another individual qualified as a technical supervisor who achieved a satisfactory score in the most recent cytology proficiency-testing event,
and the last 500 negative slides examined by an inchvidual not qualified as a technical supervisor who failed a proficiency-testing event must be re-examined by another individual who achieved a satisfactory score in the most recent cytology proficiency-testing event. However, at present there are no approved cytology proficiency-testing programs.
On May 21, 1990, HCFA published the proposed rule to implement CLIA '88, which contained the current proficiency-testing requirements as a proposal and allowed the regulated industry and all sectors of the public to comment on them. Changes in the final rule will be made in response to the concerns raised by the commentators.
Many people perceive proficiency testing as an external tool for laboratory education. Others argue that it is not an effective measure of a laboratory's day-to-day performance. Congress thinks of it as the "most important measure of a laboratory's performance." HCFA recognizes that proficiency testing is neither administratively nor scientifically without flaws or complicating factors. However, proficiency-testing results are one of the standard outcome measures used to assess laboratory performance. The CLIA statute places significant emphasis on proficiency testing as an outcome measure to gauge the performance capabilities of laboratories.
HCFA is committed to implementing
Congress's intent that proficiency testing be a central part of each regulated laboratory's quality assessment.
